News: Onyx Pharmaceuticals Inc (ONXX.OQ)

ONXX.OQ on NASDAQ Stock Exchange Global Select Market

135.58USD
4:00pm EDT
Price Change (% chg)

$4.25 (+3.24%)
Prev Close
$131.33
Open
$132.80
Day's High
$135.69
Day's Low
$132.36
Volume
1,125,711
Avg. Vol
401,280
52-wk High
$135.69
52-wk Low
$63.52

Search Stocks
Select another date:

US STOCKS-Futures point to flat open before factory data

* Fed's Dudley to speak about national economic conditions

Continue Reading

US STOCKS-Futures higher as positive momentum persists

* Fed's Dudley to speak about national economic conditions

US STOCKS-Futures higher as positive momentum persists

NEW YORK, July 2 - U.S. stock index futures rose modestly on Tuesday, indicating positive market momentum would continue as investors remain more comfortable with the economic outlook.

Pfizer, Novartis may join Amgen in bidding for Onyx: sources

NEW YORK - Onyx Pharmaceuticals Inc , whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG , two people familiar with the matter said on Monday.

Onyx explores possible sale after rejecting Amgen offer

NEW YORK - Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but still is considering selling itself.

UPDATE 4-Onyx explores possible sale after rejecting Amgen offer

NEW YORK, June 30 - Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but still is considering selling itself.

Onyx explores possible sale, rejects Amgen offer

NEW YORK - Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger rival Amgen Inc as too low but is still considering a sale of the company.

UPDATE 3-Onyx explores possible sale, rejects Amgen offer

NEW YORK, June 30 - Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger rival Amgen Inc as too low but is still considering a sale of the company.

U.S. biotech Amgen offered to buy Onyx for $120 per share: report

- Amgen Inc , the world's largest biotech company, has offered to buy biotech Onyx Pharmaceuticals for $120 per share in cash, Canadian newspaper Financial Post reported on Friday, sending Onyx shares up about 30 percent in after-hours trading.

UPDATE 1-U.S. biotech Amgen offered to buy Onyx for $120 per share -report

June 28 - Amgen Inc, the world's largest biotech company, has offered to buy biotech Onyx Pharmaceuticals for $120 per share in cash, Canadian newspaper Financial Post reported on Friday, sending Onyx shares up about 30 percent in after-hours trading.

Select another date:

Market Views

» More ONXX.OQ Market Views

Press Releases

Search Stocks